Peptide complex for maintaining bone marrow and blood formation functions

Release form: 30 capsules per pack.

The capsule is produced from a special stable polymer of a plant origin — hypromellose — without chemical impurities.

Intensified peptide complex Bone-marrowTIDE PLUS forte helps to normalize hemostasis, bone tissue metabolism, stimulate hematopoiesis processes, and prevent the risk of iron deficiency anemia.

How peptide bioregulator for bone marrow works for blood formation

Bone marrow cells play a key role in the hematopoietic system, participating in maintaining a constant amount of blood elements formation and creating new blood cells, producing various types of proteins, and regulating bone formation. They are involved in immunobiological defense mechanisms, fat, protein, vitamin and mineral metabolic reactions, and iron metabolism.

Bone-marrowTIDE PLUS supports functions of the entire hematopoietic system, regulates metabolic processes, and increases the body’s adaptive defenses. The therapeutic effect of the bioregulator is intensified with an additional amount of concentrated peptides of an animal origin, which act directly on DNA cells of hematopoietic tissues, stimulate the continuous process of blood cell formation, and restore protein synthesis processes. The composition of the complex includes minerals, vitamins, and extracts of medicinal herbs.

Peptide bioregulator for the bone marrow is effective for iron deficiency prevention, various blood diseases, disorders of the hematopoietic system caused by exposure to extreme environmental factors; in diseases due to anemia.

Eleuthero extract or Siberian ginseng (Eleutherococcus senticosus  normalizes blood pressure, increases appetite, regulates redox processes, stimulates hematopoiesis and reduces stress.

L-Arginine stimulates the production of T-lymphocytes, affects the regulation of vascular tone and the formation of new blood vessels in a tissue or organ.

Iron fumarate is necessary for the formation of hemoglobin, myoglobin and red blood cells.

Vitamin C regulates blood clotting, normalizes capillary permeability, it is necessary for hematopoiesis, and it is involved in iron metabolism.

Vitamin B6 is involved in the synthesis of hemoglobin and the formation of heme in erythroid cells in bone marrow tissue.

Vitamin B12 is necessary for normal hematopoiesis — it promotes maturation of red blood cells, activates blood coagulation system, and reduces concentration of blood cholesterol.

Folic acid stimulates blood formation by participating in the formation of red and white blood cells.

Copper is necessary for hemoglobin formation, promotes transfer of iron to the bone marrow, and activates maturation of red blood cells.

Recommendations for use (prevention and complex therapy)

• Anemia of various etiologies
• Prevention and normalization of blood formation process disorders
• As a helpful therapy component for anemic conditions, bleeding, gastrointestinal bleeding
• IDA (iron deficiency anemia) and insufficient iron food intake (for stomach diseases large intestine diseases, chronic diarrhea, during diets).
• Insufficient iron food intake or malabsorption of iron (diet, chronic diarrhea, helminthic invasion, stomach and colon diseases)
• As part of complex therapy for normalization of iron deficiency in the elderly

Method of application in complex therapy:
Adults take one capsule a day for 1 month, 30 minutes after a meal, with plenty of water. It is allowed to take the product for a longer period up to 2-3 months as a prevention therapy for iron deficiency anemia.

Contraindications: 
Increased individual sensitivity to the components; period of pregnancy and breastfeeding; underage children (due to lack of data)

IMPORTANT! Bone-marrowTIDE PLUS forte peptide complex is designed to normalize functions of the bone-marrow, blood formation processes. It is recommended as a preventive product and can be used in combination with the main course of therapy prescribed by the attending physician.

* NRVs - nutrient  reference  values

To enhance the therapeutic effect, it is recommended to combine the bioregulator with other My Real Way peptide bioregulators and peptide-polysaccharide complexes, depending on the pathology.

Program 1

Program 2

Program 3

Program 4

Program 5

Program 6

Program 7

Malignant blood diseases

To evaluate the effectiveness of the multicomponent peptide bioregulator Bone-marrowTIDE PLUS for the bone marrow, the dynamics of patients complaints were diagnosed with IDA (iron deficiency anemia). General weakness, fatigue, sweating, dizziness, noise in the ears and head, dry skin, delamination and brittle nails were studied. Also, general clinical study of blood, urine, biochemical blood test, zophagogastroduodenoscopy (EFGDS), fecal occult blood tests were conducted on patients. There were 13 patients of the main group and 13 patients of the control group aged 52-77 years.

12 patients had previously received intermittent iron supplements or some other medical drug therapy. However, this happened uncontrollably and it is not possible to judge its effectiveness. Patients in the control group received treatment using conventional means. In addition to the standard medical drugs, the patients of the main group were prescribed to intake daily multicomponent peptide bioregulator Bone-marrowTIDE PLUS, 2 capsules per day for 30-45 days, depending on the severity of the pathological process.

It was established that the use of the multicomponent peptide bioregulator Bone-marrowTIDE PLUS in all patients with IDA contributed to a decrease in the clinical development of the disease, improvement and stabilization of general clinical and biochemical blood parameters. The increase in hemoglobin level averaged 24.3 +6.7 g/l, such indicators as microcytosis, aniso- and poikilocytosis improved, the index of non-hemoglobin iron, ferritin have increased.

After a long-term complex intake (more than 30 days), the main group showed normalization of the above biochemical parameters in half of the patients. The regression of clinical symptoms in patients of the main group, compared with the control group, was faster (by 3.1+1.4 days on average). According to the results of EFGDS, erosive processes in the stomach were detected in 2 patients of the main group and in 2 patients of the control group. When re-examination on the 20-24th day after the therapy was perfomed, no erosions were detected.

A more stable and pronounced effect of improving blood parameters was observed with a longer intake of the multicomponent peptide bioregulator Bone-marrowTIDE PLUS for 40-45 days, which allows us to draw a conclusion about the dependence of the clinical effect on the duration of complex intake.

In the process of monitoring patients who received the multicomponent peptide bioregulator Bone-marrowTIDE PLUS as part of complex therapy, no side effects, complications or product dependence were detected.

The study was conducted in 2017 by certified specialists from the Department of Restorative Medicine and Nutrition of the European Scientific Society at the Academy of Natural Sciences (Hannover,Germany)